WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002029087) USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/029087    International Application No.:    PCT/US2001/030904
Publication Date: 11.04.2002 International Filing Date: 02.10.2001
Chapter 2 Demand Filed:    23.04.2002    
IPC:
G01N 33/50 (2006.01), G01N 33/74 (2006.01)
Applicants: ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. [US/US]; 736 Cambridge Street, Boston, MA 02135 (US)
Inventors: GRAVEREAUX, Edwin, C.; (US).
MARCY, Silver; (US).
ISNER, Jeffrey, M.; (US).
YOON, Young-sup; (US)
Agent: BUCHANAN, Robert, L.; Dike, Bronstein, Roberts & Cushman - IP Practice Group of Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US)
Priority Data:
60/237,171 02.10.2000 US
Title (EN) USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC DISORDERS
(FR) UTILISATION D'AGENTS LYMPHANGIOGENIQUES POUR LE TRAITEMENT DE TROUBLES LYMPHATIQUES
Abstract: front page image
(EN)The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include administering at least one vascular endothelian factor (VEGF) such as VEGF-2. In one embodiment, therapeutic methods for treating lymphedema and related disorders in a human patient are disclosed. The VEGF can be provided by any suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.
(FR)L'invention concerne des méthodes permettant de favoriser la croissance de nouveaux vaisseaux lymphatiques (lymphangiogénèse). D'une manière générale, de telles méthodes consistent à administrer au moins un facteur endothélial vasculaire (VEGF) tel que VEGF-2. Dans un mode de réalisation, l'invention concerne des méthodes thérapeutiques permettant de traiter un lymphoedème et des troubles associés chez un patient humain. Le VEGF peut être administré par un moyen approprié quelconque, notamment une injection directe d'un acide nucléique codant celui-ci ou un fragment actif de celui-ci. L'invention concerne en outre des produits pharmaceutiques favorisant la lymphangiogénèse, ainsi qu'un système d'essai permettant de balayer des composés capables d'induire une croissance de nouveaux vaisseaux lymphatiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)